Management of Staphylococcus aureus Bacteremia
JAMA · 02.09.2025 · 334 (9) · 798
DOI: 10.1001/jama.2025.4288 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift JAMA, erschienen am 02.09.2025. Verfasst von Steven Y C Tong und 3 weiteren Autor:innen. Beteiligte Einrichtung: Victorian Infectious Diseases Service, The Royal Melbourne Hospital, at the Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, …. Hauptthemen laut MEDLINE: Anti-Bacterial Agents, Bacteremia, Staphylococcal Infections, Staphylococcus aureus. Die Arbeit wurde bisher 207-mal zitiert (Crossref) und nennt 103 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAID NIH HHS.
Abstract (Originalsprache)
Importance Staphylococcus aureus , a gram-positive bacterium, is the leading cause of death from bacteremia worldwide, with a case fatality rate of 15% to 30% and an estimated 300 000 deaths per year. Observations Staphylococcus aureus bacteremia causes metastatic infection in more than one-third of cases, including endocarditis (≈12%), septic arthritis (7%), vertebral osteomyelitis (≈4%), spinal epidural abscess, psoas abscess, splenic abscess, septic pulmonary emboli, and seeding of implantable medical devices. Patients with S aureus bacteremia commonly present with fever or symptoms from metastatic infection, such as pain in the back, joints, abdomen or extremities, and/or change in mental status. Risk factors include intravascular devices such as implantable cardiac devices and dialysis vascular catheters, recent surgical procedures, injection drug use, diabetes, and previous S aureus infection. Staphylococcus aureus bacteremia is detected with blood cultures. Prolonged S aureus bacteremia (≥48 hours) is associated with a 90-day mortality risk of 39%. All patients with S aureus bacteremia should undergo transthoracic echocardiography; transesophageal echocardiography should be performed in patients at high risk for endocarditis, such as those with persistent bacteremia, persistent fever, metastatic infection foci, or implantable cardiac devices. Other imaging modalities, such as computed tomography or magnetic resonance imaging, should be performed based on symptoms and localizing signs of metastatic infection. Staphylococcus aureus is categorized as methicillin-susceptible (MSSA) or methicillin-resistant (MRSA) based on susceptibility to β-lactam antibiotics. Initial treatment for S aureus bacteremia typically includes antibiotics active against MRSA such as vancomycin or daptomycin. Once antibiotic susceptibility results are available, antibiotics should be adjusted. Cefazolin or antistaphylococcal penicillins should be used for MSSA and vancomycin, daptomycin, or ceftobiprole for MRSA. Phase 3 trials for S aureus bacteremia demonstrated noninferiority of daptomycin to standard of care (treatment success, 53/120 [44%] vs 48/115 [42%]) and noninferiority of ceftobiprole to daptomycin (treatment success, 132/189 [70%] vs 136/198 [69%]). Source control is a critical component of treating S aureus bacteremia and may include removal of infected intravascular or implanted devices, drainage of abscesses, and surgical debridement. Conclusions and relevance Staphylococcus aureus bacteremia has a case fatality rate of 15% to 30% and causes 300 000 deaths per year worldwide. Empirical antibiotic treatment should include vancomycin or daptomycin, which are active against MRSA. Once S aureus susceptibilities are known, MSSA should be treated with cefazolin or an antistaphylococcal penicillin. Additional clinical management consists of identifying sites of metastatic infection and pursuing source control for identified foci of infection.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Victorian Infectious Diseases Service, The Royal Melbourne Hospital, at the Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia.
- Department of Infectious Diseases, The University of Melbourne at the Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia.
- Division of Infectious Diseases, Duke University, Durham, North Carolina.
- Duke Clinical Research Institute, Duke University, Durham, North Carolina.
- Duke University Medical Center Library and Archives, Duke University School of Medicine, Durham, North Carolina.
Förderung
- NIAID NIH HHS
Zitieren
APA
Tong, S. Y. C., Fowler, V. G., Skalla, L., & Holland, T. L. (2025). Management of Staphylococcus aureus Bacteremia. JAMA, 334(9), 798. https://doi.org/10.1001/jama.2025.4288
Vancouver
Tong SYC, Fowler VG, Skalla L, Holland TL. Management of Staphylococcus aureus Bacteremia. JAMA. 2025;334(9):798. doi:10.1001/jama.2025.4288
BibTeX
@article{Tong2025,
author = {Tong, Steven Y C and Fowler, Vance G and Skalla, Lesley and Holland, Thomas L},
title = {Management of Staphylococcus aureus Bacteremia},
journal = {JAMA},
year = {2025},
volume = {334},
number = {9},
pages = {798},
doi = {10.1001/jama.2025.4288}
}
EUVIMED